Related Experiment Video
Updated: Apr 11, 2026
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
11.7K
Minimally required essential bio markers for lymphoma.
Shikha Ghanghoria1, Arvind Ghanghoria2, Gulladurthi Prudhvi Sai Chownika1
1Department of Pathology MGMMC MYH, Indore, Madhya Pradesh, India.
Bioinformation
|April 10, 2026
Summary
Identifying essential immunohistochemical (IHC) markers is crucial for classifying and predicting outcomes in lymphoma. This study recommends a cost-effective IHC panel for reliable lymphoma diagnosis, especially in resource-limited settings.
Area of Science:
- Hematology
- Oncology
- Immunohistochemistry
Background:
- Lymphoma encompasses diverse blood cancers with varied characteristics.
- Accurate classification and prognostication require precise diagnostic markers.
- Identifying essential immunohistochemical (IHC) markers is critical for lymphoma management.
Purpose of the Study:
- To determine a minimum essential panel of IHC markers for lymphoma classification and prognostication.
- To establish a cost-effective diagnostic approach for lymphoid malignancies.
Main Methods:
- A retrospective study analyzed 88 lymphoma cases.
- A primary panel of monoclonal antibodies including CD3, CD5, CD20, CD10, CD45, PAX-5, and Ki-67 was utilized.
- Immunohistochemical staining was performed to assess marker expression.
Main Results:
- B-cell lymphomas showed high labeling with CD20, CD45, and PAX-5.
- T-cell lymphomas were strongly positive for CD3 and CD5.
- Aggressive subtypes like Diffuse Large B-Cell Lymphoma exhibited high Ki-67 proliferation indices.
Conclusions:
- A restricted panel of IHC markers can reliably diagnose and prognosticate lymphoma.
- This approach is particularly beneficial for resource-limited settings.
- The study provides recommendations for an essential IHC marker panel for lymphoma.
